Neurocrine Q1 GAAP net loss $76.6M; INGREZZA sales $410M (+36% YoY)

NEUROCRINE BIOSCIENCES INC

2023-Q1 EPS reported -$0.79 revenue$420,400,000

INGREZZA net sales $410M, up 36% YoY; guidance reiterated at $1.67-1.77B for FY2023.
GAAP net loss $76.6M ($0.79 loss per share) vs $13.9M income in Q1 2022.
Non-GAAP net loss $49.5M ($0.51 loss per share) vs $29.7M income in prior year.
Recorded $143.9M acquired IPR&D expense for Voyager gene therapy collaboration.
Valbenazine PDUFA for Huntington chorea set for Aug 20, 2023; top-line data from crinecerfont expected early Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.